bf/NASDAQ:ELEV_icon.jpeg

NASDAQ:ELEV

Elevation Oncology, Inc.

  • Stock

USD

Last Close

0.36

22/07 22:24

Market Cap

144.25M

Beta: -

Volume Today

479.75K

Avg: 819.79K

PE Ratio

−2.16

PFCF: −1.98

    Description

    Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-...Show More

    Earnings

    Earnings per Share (Estimate*)

    -5-4-3-2-12020-03-312021-06-252022-08-042023-11-022024-08-012025-04-30

    Revenue (Estimate*)

    0.000.000.010.010.012020-03-312021-06-252022-08-042023-11-022024-08-012025-04-30

    *Estimate based on analyst consensus